Thursday, May 17, 2012
GSK melanoma drug shows promise in early trial
LONDON (Reuters) - An experimental cancer drug developed by Britain's GlaxoSmithKline may add vital months to the lives of melanoma patients whose disease has spread to their brains, according to data from an early-stage trial published on Friday. Results of Phase I trial published in The Lancet medical journal showed substantial shrinking of tumors in patients treated with the
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment